Rifapentine
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Rifapentine: From Tuberculosis to Leprosy
One-Sentence Summary
Rifapentine is a rifamycin-class antimycobacterial, established for the treatment of pulmonary tuberculosis. The TxGNN model predicts it may also be effective against leprosy (Hansen’s disease), with 20 publications — including two NEJM RCTs on single-dose post-exposure prophylaxis — currently supporting this direction, though no dedicated clinical trials for leprosy treatment are yet registered.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not on file for this market (drug currently not marketed); globally known and approved (e.g., US Priftin®) for pulmonary tuberculosis |
| Predicted New Indication | Leprosy |
| TxGNN Prediction Score | 99.77% |
| Evidence Level | L2 |
| US Market Status | Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism-of-action data is not available in the source registry for this record. Based on general pharmacological knowledge, rifapentine is a long-acting rifamycin that inhibits bacterial DNA-dependent RNA polymerase, blocking mRNA synthesis. This is the same mechanistic class as rifampicin, and its efficacy against Mycobacterium tuberculosis is well established.
Tuberculosis and leprosy are both caused by mycobacterial species (M. tuberculosis and M. leprae respectively), and the two organisms share highly conserved RNA polymerase targets. Rifampicin has long been a backbone drug in WHO multidrug therapy (MDT) for leprosy, and murine-model studies confirm that rifapentine has greater bactericidal activity against M. leprae than rifampicin. This mechanistic overlap directly supports the plausibility of the TxGNN prediction.
Clinically, this hypothesis has already moved beyond theory: a large NEJM randomized controlled trial (single-dose rifapentine in household contacts of leprosy patients) demonstrated protective, post-exposure prophylactic effect. This positions rifapentine’s leprosy-related evidence primarily in the prevention/post-exposure prophylaxis (PEP) space rather than active-disease treatment, which should be considered when interpreting the strength of this signal.
Clinical Trial Evidence
Currently no related clinical trials registered for leprosy treatment/prevention with rifapentine as a primary indication.
(Note: one tangential trial, NCT00814671, compared rifapentine dosing for pulmonary tuberculosis and is not leprosy-relevant.)
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 37195940 | 2023 | RCT | N Engl J Med | Single-dose rifapentine showed protective effect against leprosy in household contacts of patients, building on prior rifampicin PEP data |
| 37585641 | 2023 | RCT (correspondence) | N Engl J Med | Follow-up discussion/correspondence on the household-contact rifapentine PEP trial |
| 37385746 | 2023 | Cohort | BMJ Open | COMBINE protocol: population-wide active case-finding plus mass drug administration (including rifamycins) for leprosy control in “hot-spot” areas |
| 38440733 | 2024 | Review | Front Immunol | Overview of leprosy treatment, prevention, immune response, and rifampicin-resistance emergence |
| 40278757 | 2025 | Review | Trop Med Infect Dis | Review of efficacy, safety, and feasibility of rifamycin-based post-exposure chemoprophylaxis for leprosy (WHO “Towards Zero Leprosy” context) |
| 32936818 | 2020 | Preclinical | PLoS Negl Trop Dis | Mouse-footpad model: rifapentine PEP efficacy against subclinical M. leprae infection |
| 29071280 | 2017 | Preclinical/In vitro | Mol Biol Res Commun | Molecular simulation of rifabutin/rifapentine as alternatives to rifampicin in drug-resistant leprosy |
| 30207440 | 2016 | Preclinical | Indian J Leprosy | Murine-model evaluation of rifapentine (alone/combination) against rifampicin-resistant leprosy |
| 37585642 | 2023 | Correspondence | N Engl J Med | Author reply to commentary on the household-contact rifapentine PEP trial |
| 33758553 | 2021 | Observational | HIV/AIDS (Auckland) | Determinants of hepatotoxicity in HIV patients on high-dose rifapentine+isoniazid at a combined leprosy-TB treatment center |
US Market Information
Rifapentine currently has no NDA license on file in this registry (market status: Not Marketed, 0 total licenses). No product/dosage-form data available for this jurisdiction.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: A Phase 3-quality NEJM RCT plus supportive preclinical/mechanistic data (superior M. leprae bactericidal activity vs. rifampicin) justify moving forward, but the evidence base is concentrated in single-dose post-exposure prophylaxis, not confirmed active-disease treatment, and no dedicated interventional trials for leprosy treatment are registered.
To proceed, the following is needed:
- Resolve DG001 (Blocking): obtain FDA/TFDA label warnings and contraindications before any S1 safety assessment can proceed
- Resolve DG002: obtain formal DrugBank MOA record to confirm mechanistic rationale documentation
- Clarify intended use case — prophylaxis (household contacts) vs. treatment of active leprosy — as these require different evidence standards
- Assess drug-drug interaction risk given rifamycin-class enzyme induction (relevant if used in leprosy patients also on other chronic therapies)
- Confirm regulatory pathway feasibility given the drug’s current “Not Marketed” status in this jurisdiction
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.